Aprinoia Therapeutics said today that it has raised $11.1 million in a Series B round, led by KTB Network and DCI Partners.
The Taiwan-based biotech plans to use its new funds to advance the preclinical and clinical development of its tau PET imaging tracer and therapy programs for people with Alzheimer’s disease.
Get the full story at our sister site, Drug Delivery Business News.